29709-35-1

Basic information

• Product Name: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE
• Synonyms: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE;2-(1H-pyrrol-1-yl)ethylamine;2-(1H-pyrrol-1-yl)ethanamine;2-(1H-pyrrol-1-yl)ethanamine(SALTDATA: FREE);2-(1H-pyrrol-1-yl)ethan-1-aMine;1H-Pyrrole-1-ethanaMine;2-(1-pyrrolyl)ethanamine;2-pyrrol-1-ylethanamine
• CAS NO: 29709-35-1
• Molecular Formula: C₆H₁₀N₂
• Molecular Weight: 110.16
• Mol File: 29709-35-1.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 60°/0.3mm
• Flash Point: 70.5°C
• Appearance: /
• Density: 1.02g/cm³
• Vapor Pressure: 0.477mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.53±0.10(Predicted)
• CAS DataBase Reference: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE(29709-35-1)
• EPA Substance Registry System: 2-(1H-PYRROL-1-YL)-1-ETHANAMINE(29709-35-1)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 29709-35-1(Hazardous Substances Data)

Usage

Uses

2-(1H-Pyrrol-1-yl)ethanamine may be used in the preparation of dihydropyrrolo[2′,1′:3,4]pyrazino[2,1-a]isoindolones by reacting with 2-formylbenzoic acids or 2-acetylbenzoic acid via N-acyliminium cation aromatic cyclizations. This product was previously listed as CBR00085.

InChI:InChI=1/C6H10N2/c7-3-6-8-4-1-2-5-8/h1-2,4-5H,3,6-7H2

Upstream product

• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 
• 7440-44-0 pyrographite 
• 73627-16-4 N-[2-(1H-pyrrol-1-yl)ethyl]acetamide 
• 109-97-7 pyrrole 
• 689-98-5 chloroethylamine 
• 98019-88-6 3,4-Dibrom-butyraldehyd 
• 107-15-3 ethylenediamine 
• 870-24-6 2-chloroethanamine hydrochloride 
• 69309-33-7 1,4-bis-(dimethylamino)-1,3-butadiene 
• 89532-47-8 pyrrol-1-yl-acetic acid amide 
• 86241-05-6 2-(1H-pyrrol-1-yl)acetonitrile 

Downstream Products

• 945655-30-1 6-chloro-N-(2-pyrrol-1-yl-ethyl)nicotinamide 
• 112758-89-1 1-Phenyl-1,2,3,4-tetrahydropyrrolo<1,2-a>pyrazine 
• 112758-88-0 1-Benzyl-1,2,3,4-tetrahydropyrrolo<1,2-a>pyrazine 

Relevant articles and documents

Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents

Chemotherapeutic drugs currently used in clinical settings have high toxicity, low specificity, and short half-lives. Herein, polypyrrole-based anticancer drug nanocapsules were prepared by tailoring the size of the nanoparticles with a template method, controlling drug release by means of an aromatic imine, increasing nanoparticle stability through PEGylation, and improving tumor-cell selectivity by folate mediation. The nanoparticles were characterized by TEM and dynamic light scattering. α-Folate receptor expression levelsof tumor cells and normal cells were investigated by western blot and quantitative polymerase chain reaction analyses. Flow cytometry and fluorescence imaging were used to verify the cell uptake of the different-sized nanoparticles. From the different-sized polypyrrole nanoparticles, the optimally functionalized nanoparticles of 180 nm hydrodynamic diameter were chosen and further usedfor in vitroandin vivotests. The nanoparticles showed excellent biocompatibility and the drug-loaded nanoparticles exhibited effective inhibition of tumor cell growth in vitro. Moreover, the drug-loaded nanoparticles showed substantially enhanced accumulation in tumor regions and effectively inhibitedin vivotumor growth. Furthermore, the nanoparticles showed reduced doxorubicin-induced toxicity andno significant side effects in normal organs of tumor-bearing mice, as measured by body-weight shifts and evaluationof drug distribution. Overall, the functionalized nanoparticles are promising nanocarriers for tumor-targeting drug delivery.

EIS INHIBITORS

Compounds and compositions are disclosed, which are useful as inhibitors of acetyltransferase Eis, a mediator of kanamycin resistance in Mycobacterium tuberculosis.

Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.